# American Regent

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/american-regent/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | medical product supply company |
| OpenAlex ID | https://openalex.org/F4320333966 |
| Works | 413 |

## Funder papers

- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Finerenone and Kidney Outcomes in Patients With Heart Failure](https://scholariq.org/papers/finerenone-and-kidney-outcomes-in-patients-with-heart-failure/)
- [Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction](https://scholariq.org/papers/secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular-kidney-efficacy/)
- [Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF](https://scholariq.org/papers/sacubitril-valsartan-and-quality-of-life-assessed-using-the-euroqol-five/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.